{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:43:27Z","timestamp":1776523407663,"version":"3.51.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 71-year-old Japanese man was treated with 200\u00a0mg of pembrolizumab for lung adenocarcinoma with multiple bone metastases at the Department of Respiratory Medicine of Kameda General Hospital. After 19 treatment courses, he complained of epigastric pain before meals. Upper gastrointestinal endoscopy showed multiple erosions in the gastric antrum, and antacids were administered at follow-up. After 27 treatment courses, the patient underwent another endoscopy because of anorexia. The erosions were enlarged and had increased from the gastric antrum to the greater curvature of the body. Histological biopsy showed lymphocytic infiltration with a predominance of CD8-positive T cells. The patient had previously been treated for <jats:italic>Helicobacter pylori<\/jats:italic> infection, and we suspected drug-induced gastritis due to the administration of immune checkpoint inhibitors in the course of the disease. Pembrolizumab was discontinued, and the patient\u2019s symptoms gradually improved. Endoscopic examinations were performed 2, 5, and 9\u00a0months after discontinuation of pembrolizumab, and improvement in mucosal findings and decreased lymphocyte infiltration were confirmed each time. The patient has remained without any relapse of symptoms for more than 1\u00a0year after discontinuing treatment.<\/jats:p>","DOI":"10.1007\/s12328-021-01582-5","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T08:03:17Z","timestamp":1641369797000},"page":"368-373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2740-4518","authenticated-orcid":false,"given":"Keita","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayo","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Masuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"1582_CR1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"1582_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"key":"1582_CR3","doi-asserted-by":"publisher","first-page":"e00334","DOI":"10.1002\/rcr2.334","volume":"6","author":"T Onuki","year":"2018","unstructured":"Onuki T, Morita E, Sakamoto N, et al. Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol Case Rep. 2018;6:e00334.","journal-title":"Respirol Case Rep"},{"key":"1582_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/his.13118","volume":"70","author":"RS Gonzalez","year":"2017","unstructured":"Gonzalez RS, Salaria SN, Bohannon CD, et al. PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis\u2019. Histopathology. 2017;70:558\u201367.","journal-title":"Histopathology"},{"key":"1582_CR5","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.14309\/crj.2017.57","volume":"4","author":"J Boike","year":"2017","unstructured":"Boike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J. 2017;4:e57.","journal-title":"ACG Case Rep J"},{"key":"1582_CR6","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.3748\/wjg.v26.i16.1971","volume":"26","author":"HH Vindum","year":"2020","unstructured":"Vindum HH, Agnholt JS, Nielsen AWM, et al. Severe steroid refractory gastritis induced by Nivolumab: a case report. World J Gastroenterol. 2020;26:1971\u20138.","journal-title":"World J Gastroenterol"},{"key":"1582_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1159\/000491862","volume":"11","author":"Y Nishimura","year":"2018","unstructured":"Nishimura Y, Yasuda M, Ocho K, et al. Severe gastritis after administration of nivolumab and ipilimumab. Case Rep Oncol. 2018;11:549\u201356.","journal-title":"Case Rep Oncol"},{"key":"1582_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.32074\/1591-951X-24-19","volume":"111","author":"P Gaffuri","year":"2019","unstructured":"Gaffuri P, Espeli V, Fulciniti F, et al. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica. 2019;111:92\u20137.","journal-title":"Pathologica"},{"key":"1582_CR9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/CMR.0000000000000502","volume":"28","author":"RHL Yip","year":"2018","unstructured":"Yip RHL, Lee LH, Schaeffer DF, et al. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res. 2018;28:645\u20137.","journal-title":"Melanoma Res"},{"key":"1582_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41395-018-0366-3","volume":"114","author":"BB Rao","year":"2019","unstructured":"Rao BB, Robertson S, Philpott J. Checkpoint inhibitor-induced hemorrhagic gastritis with pembrolizumab. Am J Gastroenterol. 2019;114:196.","journal-title":"Am J Gastroenterol"},{"key":"1582_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s10620-020-06441-w","volume":"66","author":"Y Hayashi","year":"2021","unstructured":"Hayashi Y, Hosoe N, Takabayashi K, et al. Clinical, endoscopic, and pathological characteristics of immune checkpoint inhibitor-induced gastroenterocolitis. Dig Dis Sci. 2021;66:2129\u201334.","journal-title":"Dig Dis Sci"},{"key":"1582_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.gie.2017.04.033","volume":"86","author":"M Kobayashi","year":"2017","unstructured":"Kobayashi M, Yamaguchi O, Nagata K, et al. Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest Endosc. 2017;86:915\u20136.","journal-title":"Gastrointest Endosc"},{"key":"1582_CR13","doi-asserted-by":"publisher","first-page":"e00249","DOI":"10.14309\/crj.0000000000000249","volume":"6","author":"A Alhatem","year":"2019","unstructured":"Alhatem A, Patel K, Eriksen B, et al. Nivolumab-induced concomitant severe upper and lower gastrointestinal immune-related adverse effects. ACG Case Rep J. 2019;6:e00249.","journal-title":"ACG Case Rep J"},{"key":"1582_CR14","first-page":"90","volume":"86","author":"DM de la Mata","year":"2021","unstructured":"de la Mata DM, Busto-Bea V, Cerezo-Aguirre C. Nivolumab-induced gastritis in a patient with metastatic melanoma. Rev Gastroenterol Mex. 2021;86:90\u20131.","journal-title":"Rev Gastroenterol Mex"},{"key":"1582_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/imt-2019-0077","volume":"11","author":"A C\u01celug\u01cereanu","year":"2019","unstructured":"C\u01celug\u01cereanu A, Rompteaux P, Bohelay G, et al. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy. 2019;11:1005\u201313.","journal-title":"Immunotherapy"},{"key":"1582_CR16","first-page":"482","volume":"83","author":"J Vandepapeli\u00e8re","year":"2020","unstructured":"Vandepapeli\u00e8re J, Siplet J, Libbrecht L, et al. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient. Acta Gastroenterol Belg. 2020;83:482\u20134.","journal-title":"Acta Gastroenterol Belg"},{"key":"1582_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5858\/arpa.2019-0700-OA","volume":"145","author":"L Irshaid","year":"2021","unstructured":"Irshaid L, Robert ME, Zhang X. Immune checkpoint inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, helicobacter pylori gastritis and celiac disease. Arch Pathol Lab Med. 2021;145:191\u2013200.","journal-title":"Arch Pathol Lab Med"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-021-01582-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-021-01582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T15:35:48Z","timestamp":1648222548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-021-01582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1582"],"URL":"https:\/\/doi.org\/10.1007\/s12328-021-01582-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human\/animal rights"}},{"value":"The authors determined that approval from the hospital\u2019s ethics review committee was not necessary in this report because it involved only one case. Informed consent was obtained from the patient and his family for treatment and publication of the case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}